5 results about "Lateral ventricles" patented technology

The application belongs to the field of neuropharmacology and medicine, and particularly relates to application of taurine cholic acid in preparation of a drug for preventing or treating Alzheimer's disease. Through animal model experiment verification, the A beta lateral ventricle injection is used to prepare an AD mouse model, and after oral administration of TCA for 2 weeks, cognitive behavior and pathological indexes are significantly improved.

This invention discloses the application of the FAM26F gene in the diagnosis and treatment of depression, belonging to the interdisciplinary field of molecular biology and neuropsychiatry. This invention reveals for the first time that downregulation of the FAM26F gene expression disrupts glutamate homeostasis by affecting the expression of glutamate transporters and receptors, thereby leading to depressive-like behaviors. Based on this, this invention provides two core applications: first, the application of the FAM26F gene in the preparation of diagnostic products for depression, achieving objective diagnosis by detecting the expression level of this gene in samples such as peripheral blood; second, the application of the FAM26F gene in the preparation of therapeutic drugs for depression, wherein the drug uses a gene therapy vector that upregulates the expression of this gene as its active ingredient, and is administered via lateral ventricle injection or nasal nebulization, effectively reversing depressive-like behaviors in animal models. This invention provides a novel, precise diagnostic target and targeted treatment strategy for depression.

The application belongs to the field of image segmentation, and relates to a lateral ventricle choroid plexus segmentation and quantification method based on enhanced T1 weighted magnetic resonance images, S1: obtaining brain enhanced T1 weighted magnetic resonance images and performing pretreatment to obtain standardized brain images; S2: based on the standardized brain images, combining a preset enhancement intensity threshold and a lateral ventricle anatomical position constraint, constructing a choroid plexus candidate region; S3: using a trained choroid plexus segmentation model to perform feature discrimination and segmentation on the choroid plexus candidate region to generate an initial segmentation mask; S4: performing post-processing optimization on the initial segmentation mask to remove false positive regions to obtain a final lateral ventricle choroid plexus segmentation mask; and S5: based on the final lateral ventricle choroid plexus segmentation mask, performing choroid plexus quantification parameter calculation. The problems of low segmentation precision, poor integrity and insufficient stability are solved.

The application discloses a gene medicine for treating deafness-dystonia-optic neuropathy syndrome caused by TIMM8A gene defect and application. The medicine core is a modularly designed adeno-associated virus vector system which carries an expression cassette containing a tissue-specific promoter and a human TIMM8A treatment gene. The application realizes precise treatment through local minimally invasive injection according to different symptoms: AAV-Anc80L65-MYO15-TIMM8A is injected into the cochlea to treat sensorineural hearing loss; AAV2 / 4-Brn3b-TIMM8A is injected into the vitreous body of the eyeball to treat optic neuropathy; AAV9-hSyn-TIMM8A is injected into the central lateral ventricle to treat dystonia. Preclinical studies have confirmed that the strategy can efficiently express TIMM8A protein in the corresponding target cells, significantly repair hearing, visual and motor function defects, and correct mitochondrial dysfunction from the pathological mechanism.

The application discloses application of sh-SLK in preparation of a preparation for relieving cerebral ischemia-reperfusion injury, and relates to the technical field of gene targeting drugs. An effective active component of the preparation comprises short hairpin RNA sh-SLK capable of targeting and specifically silencing STE20-like kinase gene expression. The preparation is loaded in a recombinant virus carrier, and is formulated into a lateral cerebral ventricle injection dosage form; the preparation is delivered to brain tissues through a brain stereotactic technique, so that high-efficiency expression of sh-SLK is established in ischemic brain tissues, and then the activity of SLK is specifically inhibited.